Gilead Sciences Inc. (GILD)’s experimental HIV pill Quad may need additional monitoring because of kidney damage seen in studies, U.S. regulators said. The four-in-one combination pill from Gilead, the largest maker of AIDS drugs, had a “generally acceptable” safety profile and retained more patients than standard treatments, Food and Drug Administration staff said in a report today. The agency asked advisers whether patients taking the drug should undergo extra testing to monitor for kidney complications.
